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results of a prospective, multicenter, observational study
completed by the recently created chronic graft-versus-host
disease (cGVHD) consortium. The team of investigators
determined whether assessment of lung function, as rec-
ommended by the 2005 National Institutes of Health (NIH)
consensus conference, impacted survival and patient-
reported outcomes in adult and a small subset of pediatric
patients with cGVHD who required immune-suppressive
therapy. The investigators analyzed both components of
the NIH lung scoring system, the symptom-based and pul-
monary function test (PFT)-based scores, along with 5
additional measures of pulmonary dysfunction from longi-
tudinal data collected from 1591 visits (for 496 patients)
across 10 centers in the consortium.
Lung injury remains a signiﬁcant problem after allogeneic
hematopoietic cell transplantation (HCT) and contributes to
signiﬁcant morbidity and mortality in the months and years
that follow. Two forms of late pulmonary dysfunction have
been described: obstructive lung disease (OLD) and restric-
tive lung disease (RLD). Inconsistencies in terminology,
interchangeable (mis)-use of the terms “bronchiolitis oblit-
erans” and “bronchiolitis obliterans organizing pneumonia,”
and variable diagnostic criteria have contributed to a wide
range in the reported incidence of these complications [2].
Symptoms of late pulmonary dysfunction may include
cough, dyspnea on exertion, and wheezing, but many pa-
tients are asymptomatic until later in their disease course
when PFTs are already signiﬁcantly impaired. The develop-
ment of pulmonary toxicity has been associated with GVHD
and the intensity of HCT conditioning, suggesting that both
alloactivation and regimen-related toxicity contribute to the
chronic inﬂammation and ﬁbrosis characteristic of OLD and
RLD. The precise immunologic mechanisms responsible for
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lished, however.
The study by the cGVHD consortium revealed that when
assessed at a single time point, only the NIH symptom-based
lung score (based on the presence of shortness of breath), and
not cross-sectional PFT measurements or modest drops in
forced expiratory volume in 1 second (>10%),were associated
with overall survival and nonrelapse mortality. Perhaps even
more sobering, worsening of clinical symptoms (by even a
single point in the NIH symptom-based score) was predictive
of poor outcomes. The ﬁndings of greater evidence of pul-
monary dysfunction at enrollment based on PFTs (compared
with symptoms) and an association between shortness of
breath and worse outcomes were perhaps predictable; pa-
tients can remain asymptomatic despite signiﬁcant drops in
spirometry, and by the time they complain of dyspnea, PFTs
usually are quite impaired. In contrast, surprisingly, while
cross-sectional PFT measurements, obstructive PFT physi-
ology, and the diagnosis of bronchiolitis obilterans syndrome
were correlated with higher Lee lung symptom scores, they
were not associated with outcomes, as was reported in pre-
vious studies. However, data limitations reduced thepower of
those observations; approximately 60% of patients had no PFT
data or data from only 1 PFT, and because the number of pa-
tients with data onmore than 2 PFTs is not clear, determining
the effects of rate of change over time on outcome is difﬁcult.
In addition, information regarding diagnostic workup or any
changes in systemic therapy in patients with worsening PFTs
or clinical symptoms was not reported. Finally, only patients
with cGVHD who were receiving systemic immune-
suppressive therapy were followed in the trial.
The foregoing ﬁndings notwithstanding, the results of the
study have signiﬁcant merit. Although the performance of an
easily obtained symptom-based parameter (dyspnea) is
encouraging, the implications of these ﬁndings are sobering
and beg the question of what can be done to successfully
identify and treat patients with evolving pulmonary
dysfunction before theybecome symptomatic. Unfortunately,
standard treatments for noninfectious forms of OLD and RLD
predispose to opportunistic infection and are suboptimal; no
combination of agents has proven particularly effective. The
persisting diagnostic and therapeutic challengeswith respect
to the characterization,management, and pathophysiology of
late-onset lung toxicityhavebeen the subjectof several recent
reports [3-5] and underscore the need for a better under-
standingof thepathogenesis of, and thedevelopmentof novel
therapies for, this spectrum of lung diseases [6].
The goodnews is that newpreclinicalmodels andworking
hypotheses have been developed and currently are being
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tion, dysregulated repair, and collagen deposition character-
istic of OLD and RLD [7,8]. Furthermore, new strategies,
including the administration of etanercept (a soluble TNF-
aebinding protein) and combination therapy with ﬂutica-
sone, azithromycin, and montelukast (FAM), have shown
promise [9] and are currently undergoing further testing [10].
More remains to be done, however. For starters, consis-
tent approaches to the monitoring of pulmonary function
(including the utility of expanded use of hand-held spirom-
etry) after allogeneic HCT, diagnostic workup (including the
roles of bronchoscopy and computed tomography) of
affected patients, and classiﬁcation of lung dysfunction
(particularly RLD) once identiﬁed, along with clinical
guidelines for the initiation of inhaled or systemic therapy,
are lacking and need to be established. Furthermore, ad-
vances in radiographic imaging that may allow earlier
detection of progressive parenchymal or small airway
inﬂammation [11] and overcome limitations of available
diagnostic tools should be explored in allogeneic HCT re-
cipients with suspected OLD or RLD. Thus, steps to address
“boring” but critical knowledge gaps in standard of practice
can be complemented by cutting-edge technology and pro-
vide a platform to determine whether early detection of
pulmonary dysfunction will enhance the success of timely
intervention with novel immunomodulatory therapy. The
addition of patient sample procurement (ie, bronchoalveolar
lavage ﬂuid, plasma, and stool) at deﬁned time points in such
an endeavor will allow for clinical biomarker discovery and
exploration of nonconventional infectious etiologies of OLD
and RLD using next-generation sequencing techniques as
described for other HCT complications [12,13].
Despite the tremendous advances in transplantation
biology and clinical care over the last several decades, cGVHD
and pulmonary toxicity remain the scourges of allogeneic
HCT recipients, negatively impacting quality of life and
limiting successful outcomes. It is hoped that future ex-
ploration using animal models and the development of
innovative and comprehensive clinical trials will allow
investigators to better deﬁne and exploit the window
of opportunity for patients with late-onset pulmonaryFinancial Disclosure: None relevant to the article.
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Conditioning Allografting: Is the Beneﬁt
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Accepted 28 December 2013In the modern era, graft-versus-host disease (GVHD) and
associated nonrelapse mortality (NRM) continue to plague
allogeneic hematopoietic cell transplantation (allo-HCT)
outcomes. A variety of strategies has been developed to
preventGVHDafter allo-HCT, includingex vivo or in vivoTcell
depletion, pharmacological inhibition of Tcell proliferation or
trafﬁcking, monoclonal antibodies, and immune-modulation
(to name a few), but the best prophylactic modality remains
controversial.
In vivo T cell depletionwith antithymocyte globulin (ATG)
is commonly performedbyadministering 1 of 3 commercially
